Published in Nat Genet on January 01, 1999
The epigenomics of cancer. Cell (2007) 30.91
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J (2003) 11.27
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet (2007) 5.16
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A (2002) 4.22
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96
Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. Genes Dev (2003) 3.95
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A (2010) 3.86
Severe global DNA hypomethylation blocks differentiation and induces histone hyperacetylation in embryonic stem cells. Mol Cell Biol (2004) 3.76
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A (2000) 3.65
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res (2008) 3.16
Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med (2007) 3.05
Methylation matters. J Med Genet (2001) 3.00
Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. J Cell Biol (2001) 2.94
Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol (2003) 2.72
DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nat Genet (2017) 2.67
Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet (2008) 2.55
The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev (2001) 2.48
Targeting DNA methylation. Clin Cancer Res (2009) 2.45
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
Leukaemogenesis: more than mutant genes. Nat Rev Cancer (2010) 2.16
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood (2010) 2.15
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A (2007) 2.11
Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell (2009) 2.09
Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol (2003) 2.04
Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci U S A (2001) 1.93
A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res (2012) 1.92
CpG island methylation in colorectal adenomas. Am J Pathol (2001) 1.88
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
Identification of Arabidopsis histone deacetylase HDA6 mutants that affect transgene expression. Plant Cell (2001) 1.87
Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest (2004) 1.87
Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res (2009) 1.87
CpG methylation as a mechanism for the regulation of E2F activity. Proc Natl Acad Sci U S A (2000) 1.86
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer (2006) 1.77
An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One (2008) 1.76
Molecular mechanisms of gene silencing mediated by DNA methylation. Mol Cell Biol (2002) 1.73
Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer. Cancer Biol Ther (2009) 1.72
Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation. Mol Cell Biol (2001) 1.70
Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res (2008) 1.69
The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc Natl Acad Sci U S A (2003) 1.69
Retracted The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest (2004) 1.68
Dynamic analysis of proviral induction and De Novo methylation: implications for a histone deacetylase-independent, methylation density-dependent mechanism of transcriptional repression. Mol Cell Biol (2000) 1.67
Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) (2010) 1.66
Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol (2002) 1.64
Epigenetic silencing of somatostatin in gastric cancer. Dig Dis Sci (2010) 1.61
Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2. Cancer Res (2009) 1.61
GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol (2001) 1.60
Regulation of human fetal hemoglobin: new players, new complexities. Blood (2005) 1.60
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol (2008) 1.59
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res (2006) 1.58
Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A (2003) 1.57
Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol (2002) 1.56
Epigenetic alterations in human prostate cancers. Endocrinology (2009) 1.55
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood (2010) 1.53
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer (2008) 1.52
CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One (2009) 1.52
Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. Nucleic Acids Res (2006) 1.52
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res (2008) 1.51
Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol (2008) 1.48
Demethylating agents in myeloid malignancies. Curr Opin Oncol (2008) 1.48
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One (2006) 1.48
The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer (2003) 1.48
Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res (2002) 1.47
Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One (2008) 1.46
Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol (2002) 1.46
Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: the predominant role of hMLH1. Proc Natl Acad Sci U S A (1999) 1.45
Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc Natl Acad Sci U S A (2006) 1.43
DNA demethylation. Proc Natl Acad Sci U S A (1999) 1.43
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42
Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer (2005) 1.40
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene (2011) 1.38
Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leuk Res (2009) 1.37
Epigenetics in breast cancer: what's new? Breast Cancer Res (2011) 1.36
Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. Proc Natl Acad Sci U S A (2008) 1.36
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res (2012) 1.35
SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities. Mol Cell Biol (2011) 1.35
MeCP2 driven transcriptional repression in vitro: selectivity for methylated DNA, action at a distance and contacts with the basal transcription machinery. Nucleic Acids Res (2000) 1.34
Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther (2005) 1.34
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol (2011) 1.34
DNA mismatch repair genes and colorectal cancer. Gut (2000) 1.34
Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Oncogene (2011) 1.34
The role of AUF1 in regulated mRNA decay. Wiley Interdiscip Rev RNA (2011) 1.34
Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention. Ann Rheum Dis (2007) 1.31
Epigenetic gene silencing in cancer. J Clin Invest (2000) 1.28
The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol (2010) 1.28
MS-qFRET: a quantum dot-based method for analysis of DNA methylation. Genome Res (2009) 1.28
Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol (2006) 1.26
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res (1998) 8.95
A gene hypermethylation profile of human cancer. Cancer Res (2001) 8.93
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 6.57
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res (1999) 6.10
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet (2000) 5.72
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (2001) 4.99
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res (1998) 4.39
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet (2001) 3.96
Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A (1998) 3.80
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet (2001) 3.76
Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res (2000) 3.65
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res (1996) 3.50
Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res (1999) 3.48
Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem (2001) 3.23
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res (1994) 3.18
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res (1997) 3.09
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97
CpG methylation is maintained in human cancer cells lacking DNMT1. Nature (2000) 2.94
Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res (2001) 2.79
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 2.79
Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res (1999) 2.62
Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood (1999) 2.57
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res (2001) 2.50
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol (2001) 2.48
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med (1995) 2.47
Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (1999) 2.34
Methylation-specific PCR simplifies imprinting analysis. Nat Genet (1997) 2.33
An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature (1997) 2.29
Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem (1997) 2.27
De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol Cell Biol (1996) 2.26
DNA methylation, chromatin inheritance, and cancer. Oncogene (2001) 2.26
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res (2000) 2.18
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res (1999) 2.17
The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. Proc Natl Acad Sci U S A (1988) 2.14
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer (2008) 2.13
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res (1997) 2.12
Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res (1992) 2.10
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res (1999) 2.09
High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci U S A (1991) 2.07
Conservation of the Drosophila lateral inhibition pathway in human lung cancer: a hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proc Natl Acad Sci U S A (1997) 2.00
Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci U S A (1996) 1.99
MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene (1998) 1.99
Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Natl Acad Sci U S A (1993) 1.97
Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res (2001) 1.97
Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res (2000) 1.95
Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst (1993) 1.94
Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res (2000) 1.91
Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res (1998) 1.91
Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc Natl Acad Sci U S A (1993) 1.86
Molecular markers of neuroendocrine development and evidence of environmental regulation. Proc Natl Acad Sci U S A (1987) 1.84
Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene (2000) 1.83
Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer. Science (1983) 1.83
Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res (1995) 1.82